Cardio-hepatic syndrome in patients undergoing transcatheter aortic valve replacement.

ABSTRACT:

Background

Cardiohepatic syndrome (CHS) has been identified as an important but underrecognized survival predictor in multiple cardiovascular disease entities. The objectives of this study were to evaluate the prevalence and prognostic value of CHS in patients undergoing TAVR for severe aortic stenosis (AS).

Methods

The study included patients with available laboratory parameters of hepatic function who underwent TAVR from July 2013 until December 2019 at our center. CHS was defined as an elevation of at least two of three laboratory cholestasis parameters above the upper limit of normal (bilirubin, alkaline phosphatase, and gamma glutamyl transferase). Study endpoints were three-year survival, technical and device failure (VARC 3), as well as New York Heart Association (NYH

SUBMITTER: Stolz L 

PROVIDER: S-EPMC10562337 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature